Antibody-drug conjugates targeting CD248 inhibits liver fibrosis through specific killing on myofibroblasts.
Shaojie LiuDonghui HanChao XuFa YangYu LiKeying ZhangXiaolong ZhaoJiayu ZhangTong LuShiqi LuChanghong ShiRui ZhangAn-Gang YangAizhi ZhaoWeijun QinBo YangWeihong WenPublished in: Molecular medicine (Cambridge, Mass.) (2022)
Our study demonstrated that CD248 could be an ideal target for myofibroblasts in liver fibrosis, and CD248-targeting IgG78-DM1 had excellent anti-fibrotic effects in mice with liver fibrosis. Our study provided a novel strategy to treat liver fibrosis and expanded the application of ADCs beyond tumors.